What you should know about the treatment.

There are no age or gender limits and almost no contraindications to the use of the OraLhCG Method of the Dr. Belluscio Center for the treatment of obesity. Tolerance to the protocol is excellent and most patients undergo the treatment a second time. Weight loss is safe and comfortable for individuals, as long as they follow the diet meticulously. Any deviation from the protocol can lead to poor results. Even the smallest deviations can cause unwanted setbacks.

The OralhCG protocol is an appropriate approach to the treatment of obesity that includes a program of behavior modification and pharmacological and dietary aspects. When correctly applied the result is rapid weight loss and improved body contouring. Clinical complications and unfavorable outcomes may be related to unsafe protocol modifications.

Evidence suggests that hCG promotes fat mobilizing activity. Since hCG does not mobilize adipose cell deposits in vitro, it has been theorized that the hypothalamic region may be the intermediary organ in the lipolytic (fat mobilizing) action of hCG.

The OralhCG Method under Master Prescription includes patient follow-up (daily visits to the doctor to receive injections or oral medication, clinical control and weight) and therapeutic support during the behavior modification program.

There are some similarities between the behavioral control included in the hCG protocol and the behavior modification program in the treatment of obesity.
The 500 Kcal. diet described in the original protocol has been shown to be effective and safe.

The results have not been improved by any other obesity treatment. Body contouring remodeling is most marked in those patients with adipose ginoid distribution (fatty deposits in the areas of the hips and buttocks).

How hCG works in the treatment of obesity and overweight.

The patient feels very well throughout the treatment period. No irritability or discomfort despite being on a low-calorie diet.
The treating physician can safely and comfortably manage a very low-calorie diet.
All weight loss is done ONLY at the expense of fat tissue, no loss of muscle or bone mass.
As a result, the remodeling of the body contour is noticeable in a short period of time.
The maintenance period is more stable, with about 15-20 % of the patients who do not retain the original overweight, it can be repeated without any contraindication in this regard.
• It can be repeated without any type of contraindication in this regard.

hCG has a metabolic action on the metabolism of adipose tissue.

Over the years, it has been shown that hCG has actions on tissues other than gonadales: Kaposi’s Sarcoma, asthma, psychosis, arteriopathies, thalassemia, osteopenia, alcoholism, glaucoma. The available information would indicate that hCG can increase the release of fats in human adipose tissue through its inhibitory effect of lipogenesis.

The available information would indicate that hCG may increase the release of fats in human adipose tissue through its inhibitory effect on lipogenesis.

Pharmacological nature of hCG

The Chorionic Gonadotropin (hGC) used in the Oral hGC Method under Master Recipe is a glycoprotein (succession of amino acids linked by sugar bridges), secreted by the cells of the placenta. It is therefore a substance of natural origin common to the entire human race, with which we have had contact since the moment of our conception.

It is therefore a substance of natural origin common to the entire human species, with which we have had contact from the moment of our conception.

Although it is produced in very large quantities by the placenta, it is also found under normal conditions both in non-pregnant women and in men, bacteria and plants.

Discovered in 1927, it has been in the World Pharmacopoeia for more than 80 years.
Since then, thousands of articles have been published about the effect of hCG on the gonads (testicles or ovaries), but only a small number of these have investigated its enormous therapeutic potential in diseases such as Kaposi's sarcoma, asthma, arterial diseases, thalassemia, osteopenia, glaucoma, and cancer.
hCG is one of the few naturally occurring medicines that, fortunately, still remains in the mainstream Pharmacopoeia. However, most of the research done was on its therapeutic potential related to the testes or ovaries, with relatively little research done in other clinical fields.

Other indications in addition to fertility treatment

  • Alcoholism

  • Diabetes

  • Glaucoma

  • Breast Cancer Prevention

  • Benign prostatic hypertrophy

  • Hypercholesterolemia

  • Obesity-associated non-insulin-dependent diabetes


It was said that hCG should not be used in the case of hormone-dependent tumors, this contraindication has been refuted, since it is currently used for the preventive treatment of breast cancer, and in the case of testicles that have not descended (cryptorchidism).
hCG should not be used for ovulation induction in patients with ovarian hyperstimulation.
Secondary and adverse reaction.
Ovarian hyperstimulation after a combined application of hCG 1500 and Clomiphene.
Toxic effects of hCG in humans: unknown.
Carcinogenic, teratogenic and mutagenic activity of hCG: have not been reported.
Injection site reactions such as bruising, pain, redness, swelling, and itching have been reported. Local allergic reactions have occasionally been reported, mainly manifested as pain and/or rash at the injection site
No type of reactions such as those mentioned above have been described with oral administration.
In women: unwanted ovarian hyperstimulation, ovarian hyperstimulation syndrome, only when associated with other hormonal substances for fertility treatment.
In man: Water and sodium retention have been observed very rarely after administration of large doses; this is considered to be a result of excessive androgen production.
Mutagenesis There is no information of higher rates of malformations after ovulation induction with hCG in women.
Overdose Acute toxicity of hCG is nil and no evidence of acute overdose has been reported to date.
Drug interactions: none have been reported
Interactions with other products: not described.
If intentional ovarian hyperstimulation occurs, it has been caused by joint treatment with HMG or clomiphene.
Changes in laboratory test results: have not been reported.
Effects on ability to use machines and drive: As far as is known, this medication does not cause drowsiness or affect concentration.

The hypothalamic region and hCG

One of the strongest hypotheses about the genesis of obesity postulates that the basis of this metabolic disorder lies in the hypothalamic region: as in any other clinical disorder, it is necessary to find out who is the “villain” in this story. For example: the pancreas in diabetes, the thyroid in hypothyroidism, the adrenal glands in Addison’s disease.

The organ most frequently implicated in the genesis of the accumulation of adipose deposits appears to be the hypothalamus, and this hypothesis is supported by a strong body of clinical evidence and clinical studies.

It is interesting to note that exogenously administered hCG accumulates in the hypothalamic region, particularly in the ventromedial and lateral areas of the hypothalamus. Therefore, it is not irrational to assume that the “white” area of the metabolic actions of hCG may be the diencephalon.

Based on the evidence, hCG can act at the diencephalic level, probably modifying certain metabolic pathways of some neuropeptides, which in turn would act either in the ventromedial or lateral nucleus of the hypothalamus, or through the hypothalamus-pituitary axis.

A word of caution for those interested in the OrahlhGC Method under Masterly Prescription for the treatment of overweight; Just as diabetes cannot be improved by simply dieting, obesity cannot be treated without some form of diencephalon action.

After many years of experience in the use of hCG for the management of obesity we come to the following conclusions:

The hCG is not a magic wand
It does not cure or eradicate obesity. However, weight loss is rapid, comfortable for the patient and makes the maintenance period more stable.
There is no difference in weight loss between patients treated with hCG and those on a simple diet. The difference lies in the fact that under the action of hCG only superfluous fat is lost, and not structural fat.
Obesity may not be simply an overweight issue. Diet per se is not a treatment for obesity, but an ancillary procedure.
Unless the underlying diencephalic disorder is treated, any dietary procedure is doomed to failure.

Just as diabetes cannot be improved by simply dieting, obesity cannot be treated without some form of diencephalon action.

Anorectics point in that direction, and were for many years an unsuccessful treatment because of their side effects.

Dr. Simeons (who was the author of the Method in injectable form) never claimed that weight loss with hCG treatment was greater than patients not treated with hCG. What he suggested was that hCG, acting at the hypothalamic level, could correct the underlying diencephalic disorder, and thus the metabolism of adipose tissue.

If this were the case, hCG would be an excellent adjuvant procedure for the management of this pathology.

Why is it important to know that obesity and overweight are not the same?

Although they have been used interchangeably for many years, we now know that obesity and overweight do not refer to the same disorder:

Overweight is the weight registered on a scale above the standard values, while obesity is the ability that the organism has developed, due to a disorder in the diencephalon or hypothalamus, to accumulate more than it needs to live, as described exemplified in this image.

You see that the two subjects have the same body mass index, however the weight gain in the subject on the left is due to an increase in lean or muscle mass, while in the one on the right it is due to an increase in of fat mass.

The one on the right is overweight. The one on the left is a manifest obesity